# TUBB4A-v1: Quality Review (10-Dimension Framework)

**Competency Question:** "Which therapeutic interventions, clinical phenotypes, and biological pathways are connected to the TUBB4A gene in the context of Hypomyelination with Atrophy of the Basal ganglia and Cerebellum (H-ABC), and how do its molecular interactions explain the disease pathology?"

**CQ Slug:** tubb4a-v1
**Template:** Template 1 (Single-gene disease mechanism + therapeutic landscape)
**Protocol:** Fuzzy-to-Fact v1
**Review Date:** 2026-02-22

---

## Quality Assessment Framework (10 Dimensions)

### Dimension 1: CURIE Resolution

**Score: 9/10 | PASS**

The knowledge graph contains 27 nodes. All entity types were resolved to standard CURIEs with the exception of one investigational compound:

| Entity Type | Count | CURIEs Resolved | Missing | Prefix Used |
|-------------|-------|-----------------|---------|-------------|
| Genes (HGNC) | 8 | 8/8 (100%) | 0 | HGNC: |
| Genes (Ensembl cross-ref) | 8 | 8/8 (100%) | 0 | ENSG |
| Genes (UniProt cross-ref) | 8 | 8/8 (100%) | 0 | UniProtKB/accession |
| Genes (Entrez cross-ref) | 8 | 8/8 (100%) | 0 | NCBIGene |
| Protein | 1 | 1/1 (100%) | 0 | UniProtKB: |
| Diseases | 2 | 2/2 (100%) | 0 | Orphanet:, MONDO: |
| Target | 1 | 1/1 (100%) | 0 | CHEMBL: |
| Compound | 1 | 0/1 (0%) | nL-TUBB4-001 | ASO: (non-standard) |
| Pathways | 10 | 10/10 (100%) | 0 | WP: |
| Clinical Trials | 4 | 4/4 (100%) | 0 | NCT: |

**Resolved total: 26/27 (96.3%)**

**Details:**

- All 8 gene nodes have complete HGNC IDs with Ensembl, UniProt, Entrez, OMIM, and chromosomal location cross-references. Primary gene TUBB4A (HGNC:20774) additionally has BioGRID (115655), ChEMBL target (CHEMBL3838), and DrugBank (DB11638) identifiers.
- Disease nodes carry both Orphanet and MONDO CURIEs: H-ABC as Orphanet:139441 / MONDO:0012905, DYT4 as Orphanet:98805 / MONDO:0007493. OMIM cross-references also present (612438, 128101).
- The ASO compound nL-TUBB4-001 uses a non-standard `ASO:` prefix because it is an investigational N-of-1 therapy from the n-Lorem Foundation, not yet registered in ChEMBL or PubChem. This is a justified absence, not a protocol failure.
- All 10 pathway nodes use valid WikiPathways CURIEs (WP:WP2652, WP:WP1892, WP:WP4124, WP:WP4075, WP:WP1859, WP:WP2359, WP:WP2038, WP:WP2059, WP:WP3498 in report though not all in graph).

**Score justification:** 1 point deducted for the non-standard ASO compound CURIE, though this is documented and justified.

---

### Dimension 2: Source Attribution

**Score: 9/10 | PASS**

Source attribution was assessed by examining `[Source: tool(param)]` citations throughout the report.

| Criterion | Assessment |
|-----------|------------|
| Claims with `[Source: tool(param)]` citations | >90% |
| Sections with systematic source attribution | 11/11 report sections |
| Knowledge graph edge `source_tool` properties | 27/27 edges attributed |
| Claims without explicit tool citations | <10% |
| Training knowledge used | None detected |
| Fabricated data | None detected |

**Detailed citation audit:**

- **Section 1 (Executive Summary):** 4 explicit source citations covering UniProt, Entrez, Open Targets, STRING, and ClinicalTrials.gov.
- **Section 2 (Entity Resolution):** Complete table with per-row source attribution for all 11 properties of TUBB4A and all 4 disease entities.
- **Section 3 (Protein Function):** 3 citations to UniProt and Entrez gene data.
- **Section 4 (Interaction Network):** STRING interaction table cites `string_get_interactions(STRING:9606.ENSP00000264071)`. All 7 secondary entities cite `hgnc_get_gene()` for enrichment. Pathway tables cite `wikipathways_get_pathways_for_gene()`.
- **Section 5 (Mechanism):** All 6 mechanism subsections include `[Source:]` citations with evidence grade annotations.
- **Section 6 (Therapeutic Landscape):** All 4 NCT IDs cite `clinicaltrials_get_trial()`. Open Targets drug data cites GraphQL query.
- **Section 10 (Evidence Grading):** 10 graded claims, each with justification.
- **Section 11 (Validation):** Cross-reference table and trial verification table with status.

**Minor gap:** Some interaction role descriptions (e.g., "MAPT stabilizes microtubules," "GJA1 trafficking along microtubules") paraphrase well-established biochemistry inferred from STRING interaction annotations rather than directly quoting tool text verbatim. These are faithful paraphrases with upstream citations -- acceptable per the skill spec's paraphrasing-vs-hallucination standard.

---

### Dimension 3: LOCATE-RETRIEVE Pattern Compliance

**Score: 9/10 | PASS**

The LOCATE-RETRIEVE pattern was assessed by examining whether entities were first identified (searched/located) and then retrieved by ID.

| Phase | LOCATE Step | RETRIEVE Step | Status |
|-------|-------------|---------------|--------|
| ANCHOR (Gene) | `hgnc_search_genes("TUBB4A")` | `hgnc_get_gene(HGNC:20774)` | Documented |
| ANCHOR (Protein) | Cross-ref from HGNC | `uniprot_get_protein(UniProtKB:P04350)` | Documented |
| ANCHOR (Entrez) | Cross-ref from HGNC | `entrez_get_gene(NCBIGene:10382)` | Documented |
| ENRICH (Ensembl) | Cross-ref from HGNC | `ensembl_get_gene(ENSG00000104833)` | Documented |
| ENRICH (Disease) | Inferred from OT associations | `opentargets_get_associations(ENSG00000104833)` | Documented |
| EXPAND (STRING) | `string_search_proteins("TUBB4A")` (implied) | `string_get_interactions(STRING:9606.ENSP00000264071)` | Documented |
| EXPAND (Secondary genes) | Cross-ref from STRING | `hgnc_get_gene(HGNC:ID)` for all 7 interactors | Documented |
| EXPAND (Pathways) | N/A (gene-to-pathway lookup) | `wikipathways_get_pathways_for_gene("TUBB4A")` | Documented |
| TRAVERSE_DRUGS | Cross-ref from HGNC | `opentargets_get_target(ENSG00000104833)` | Documented |
| TRAVERSE_TRIALS | `clinicaltrials_search_trials("TUBB4A leukodystrophy")` | `clinicaltrials_get_trial(NCT:ID)` for all 4 trials | Documented |

**Observations:**
- Gene resolution followed proper HGNC search-then-get. The report explicitly shows `hgnc_search_genes("TUBB4A")` in the Entity Resolution table.
- Cross-references from HGNC RETRIEVE output (Ensembl, UniProt, Entrez) were used directly for subsequent RETRIEVE calls. This is acceptable per the skill spec: "Cross-references from RETRIEVE output can be used directly."
- STRING interactions were retrieved by protein ID after resolution. The STRING search step is implied but not explicitly cited in the report.
- All 7 secondary interactors received `hgnc_get_gene()` enrichment.
- Clinical trial search preceded individual trial retrieval.

**Minor gap:** The STRING LOCATE step (`string_search_proteins`) is not explicitly cited. The report jumps to `string_get_interactions(STRING:9606.ENSP00000264071)` using the ENSP ID from Ensembl cross-reference. This is a presentation gap, not a protocol failure, since the STRING protein ID was derived from the Ensembl cross-reference chain.

---

### Dimension 4: Disease CURIE

**Score: 10/10 | PASS**

| Criterion | Assessment |
|-----------|------------|
| Primary disease CURIE (MONDO) | MONDO:0012905 (Hypomyelinating leukodystrophy 6 / H-ABC) |
| Primary disease CURIE (Orphanet) | Orphanet:139441 |
| Secondary disease CURIE | MONDO:0007493 / Orphanet:98805 (DYT4 dystonia) |
| OMIM cross-reference | OMIM:612438 |
| CURIE used in OT associations query | Yes -- `opentargets_get_associations(ENSG00000104833)` |
| CURIE present in KG disease nodes | Yes -- 2 disease nodes with full identifiers |

Both H-ABC (MONDO:0012905, Orphanet:139441) and DYT4 (MONDO:0007493, Orphanet:98805) are resolved with proper CURIE formatting. The disease nodes appear in both the report (Section 2.2 Disease Entities table) and the knowledge graph JSON (nodes at indices 9-10). Open Targets association scores are documented: H-ABC at 0.76-0.77, DYT4 at 0.72-0.74.

---

### Dimension 5: Open Targets Pagination

**Score: 8/10 | PASS**

| Criterion | Assessment |
|-----------|------------|
| OT knownDrugs queried | Yes -- `opentargets_get_target(ENSG00000104833)` |
| Total drugs returned | 3,956 entries reported |
| Pagination pattern | Not explicitly documented |
| Data completeness | Drug count matches OT target data |

**Observations:**
- The report states "3,956 drug entries" from Open Targets knownDrugs for CHEMBL:CHEMBL3838. This indicates the full dataset was accessed.
- The report correctly identifies these as broad oncology tubulin inhibitors, presenting a representative sample of 10 drugs (paclitaxel, docetaxel, vinblastine, etc.) rather than attempting to enumerate all 3,956.
- The `size` parameter usage is not explicitly documented in the report citations.
- Given that H-ABC has no approved drugs and the oncology drugs are explicitly flagged as contraindicated, pagination was not critical to the CQ answer. The important finding was the ASO therapy from ClinicalTrials.gov, not the OT drug list.

**Score justification:** 2 points deducted because the pagination parameter (`size`, `index`) usage is not documented, even though the data appears complete. For a disease with limited H-ABC-specific drugs, this is a minor gap.

---

### Dimension 6: Evidence Grading

**Score: 9/10 | PASS**

| Criterion | Assessment |
|-----------|------------|
| Grading system used | L1-L4 scale |
| Individual claim grading | 10 claims graded in Section 10 table |
| Grade distribution | L1: 3 claims, L2: 4 claims, L3: 3 claims, L4: 0 claims |
| Overall confidence score | 0.82 (stated as median) |
| Definitions provided | Yes -- L1 through L4 defined in Section 10 |
| Per-mechanism grades | Yes -- Sections 5.1-5.6 each include evidence grade |

**Grading audit:**

| Claim | Assigned Grade | Reviewer Assessment |
|-------|---------------|---------------------|
| TUBB4A mutations cause H-ABC | L1 | Correct -- OMIM, OT, Entrez all confirm |
| TUBB4A-TUBA4A heterodimer critical | L1 | Correct -- biochemically established |
| MAPT stabilizes TUBB4A microtubules | L1 | Correct -- extensively studied |
| ASO therapy targets TUBB4A | L2 | Correct -- active trials but investigational |
| Disrupted dynein transport in H-ABC | L2 | Correct -- strong interaction data, indirect for H-ABC |
| TOR1A-TUBB4A dystonia link | L2 | Correct -- genetic + STRING evidence |
| GJA1 trafficking disruption | L3 | Correct -- inference from interaction |
| ARHGEF2 RhoA aberrant signaling | L3 | Correct -- inference from interaction |
| Tubulin code alterations | L3 | Correct -- pathway membership only |
| Oncology drugs contraindicated | L2 | Correct -- logical deduction from mechanism |

**Minor gap:** The grading uses L1-L4 section-level labels rather than claim-level numeric scores (0.00-1.00). The overall confidence of 0.82 is stated but individual numeric scores per claim are not provided. This is acceptable per the skill spec ("Section-level grading (L1-L4) if claim-level grading not feasible") but falls slightly short of ideal claim-level numeric grading.

---

### Dimension 7: Gain-of-Function Filter

**Score: N/A (Correctly Identified as Not Applicable)**

H-ABC is caused by **dominant-negative** mutations in TUBB4A, not gain-of-function mutations. The disease mechanism involves mutant TUBB4A protein incorporating into alpha-beta tubulin heterodimers and destabilizing microtubules from within (a "poison subunit" effect). This is the opposite of gain-of-function: the mutation impairs normal protein function rather than creating aberrant new activity.

The report correctly identifies this distinction in Section 6.3:
> "These agents are contraindicated in H-ABC because the disease arises from dominant-negative dysfunction rather than overactivity."

And in Section 5.1:
> "Mutations in TUBB4A are predicted to disrupt this heterodimer interface in a dominant-negative fashion, producing poisoned dimers."

The GoF filter is designed to exclude agonists from drug lists for gain-of-function diseases. Since H-ABC is not a GoF disease, this filter does not apply. The report appropriately focuses on ASO therapy (which targets the mutant transcript) rather than inhibitors.

**Score excluded from overall average.**

---

### Dimension 8: Trial Validation

**Score: 9/10 | PASS**

All 4 NCT IDs cited in the report were verified via `clinicaltrials_get_trial()`:

| NCT ID | Title | Type | Status (per report) | Source Citation | Verified |
|--------|-------|------|---------------------|-----------------|----------|
| NCT07222371 | nL-TUBB4-001 ASO for TUBB4A Leukodystrophy (UCSD) | INTERVENTIONAL | ACTIVE_NOT_RECRUITING | `clinicaltrials_get_trial(NCT:07222371)` | YES |
| NCT06369974 | ASO Treatment for TUBB4A Leukodystrophy (MGH/n-Lorem) | INTERVENTIONAL | NOT_YET_RECRUITING | `clinicaltrials_get_trial(NCT:06369974)` | YES |
| NCT02699190 | LeukoSEQ: WGS for Leukodystrophies (CHOP) | OBSERVATIONAL | COMPLETED | `clinicaltrials_get_trial(NCT:02699190)` | YES |
| NCT03047369 | Myelin Disorders Biorepository (CHOP) | OBSERVATIONAL | RECRUITING | `clinicaltrials_get_trial(NCT:03047369)` | YES |

**Detailed verification:**

- **NCT07222371**: Report correctly states sponsor (UC San Diego), intervention (nL-TUBB4-001 intrathecal ASO), start date (2025-09-19), completion (September 2027), study design (single-participant, open-label), and primary outcome measures (BAD, BFMDRS, GMFM-88, Vineland). KG node properties match.
- **NCT06369974**: Report correctly states sponsor (MGH), collaborator (n-Lorem Foundation), status (NOT_YET_RECRUITING), eligibility (age >= 4 years, confirmed TUBB4A mutation + H-ABC phenotype), and outcome measures (GMFM88, HINE-1/2, Bayley-4, Vineland-3, Tardieu). KG node properties match.
- **NCT02699190**: Report correctly identifies as completed observational study (2017-2023) from CHOP for WGS-based leukodystrophy diagnosis.
- **NCT03047369**: Report correctly identifies as recruiting observational study (2016-2030) from CHOP with key collaborators including Foundation to Fight H-ABC, Biogen, and Ionis Pharmaceuticals.

**Minor gap:** Independent verification of these NCT IDs against the live ClinicalTrials.gov database was not performed during this review. The verification relies on the tool output citations in the report and KG edge provenance. All 4 NCT IDs follow valid ClinicalTrials.gov formatting (7-8 digit numbers after NCT prefix). The descriptions are internally consistent and plausible.

---

### Dimension 9: Completeness

**Score: 8/10 | PASS**

**CQ decomposition and coverage:**

The competency question asks: "Which therapeutic interventions, clinical phenotypes, and biological pathways are connected to the TUBB4A gene in the context of H-ABC, and how do its molecular interactions explain the disease pathology?"

| CQ Component | Report Section | Status |
|--------------|----------------|--------|
| Therapeutic interventions | Section 6 (ASO trials, oncology drugs, diagnostic studies) | COMPLETE |
| Clinical phenotypes | Section 7 (H-ABC and DYT4 phenotypes with outcome measures) | COMPLETE |
| Biological pathways | Section 4.3 (14+ WikiPathways for TUBB4A and MAPT) | COMPLETE |
| Molecular interactions | Section 4.1 (7 STRING interactors with scores) | COMPLETE |
| Disease pathology explanation | Section 5 (6 mechanistic subsections linking interactions to H-ABC) | COMPLETE |

**Fuzzy-to-Fact protocol phase coverage:**

| Phase | Status | Details |
|-------|--------|---------|
| Phase 1 (ANCHOR) | COMPLETE | TUBB4A resolved via HGNC with 9+ cross-references |
| Phase 2 (ENRICH) | COMPLETE | UniProt function, Ensembl coordinates, disease associations |
| Phase 3 (EXPAND) | COMPLETE | 7 STRING interactors, all enriched via HGNC; 14+ pathways |
| Phase 4a (TRAVERSE_DRUGS) | COMPLETE | OT knownDrugs (3,956 entries) + ASO compound |
| Phase 4b (TRAVERSE_TRIALS) | COMPLETE | 4 NCT IDs retrieved and detailed |
| Phase 5 (VALIDATE) | COMPLETE | Cross-reference validation table; trial verification table |
| Phase 6 (PERSIST) | PARTIAL | KG JSON produced; no Graphiti persistence |

**Gaps identified:**

1. **PubMed full-text analysis not performed** (-1 point): Section 9 lists 13 PMIDs from Entrez and HGNC but no articles were retrieved for content via `query_pubmed`. This means functional characterization of TUBB4A mutations relies on database annotations rather than primary literature evidence.
2. **BioGRID interactions not queried** (-0.5 point): BioGRID ID (115655) was identified via UniProt but interactions were not retrieved. BioGRID physical interaction data could have complemented STRING evidence.
3. **No Graphiti persistence** (-0.5 point): KG was serialized to JSON but not persisted to the Neo4j/Graphiti backend (Phase 6 partial).

---

### Dimension 10: Hallucination Risk

**Score: 9/10 | PASS (LOW RISK)**

| Risk Factor | Assessment |
|-------------|------------|
| Claims traceable to tool output | >95% |
| Claims from training knowledge | 0% detected |
| Fabricated NCT IDs | 0 (all 4 verified via tool citations) |
| Fabricated CURIEs | 0 (all from tool output) |
| Fabricated drug names/IDs | 0 |
| Statistical claims without source | 0 |
| Speculative claims without qualification | 0 |

**Semantic equivalence audit of key claims:**

| Report Claim | Tool Source | Assessment |
|--------------|------------|------------|
| "444 amino acids" (Section 3) | UniProt P04350 | Verifiable protein property -- PASS |
| "STRING score 0.983 for TUBA4A" | string_get_interactions output | Numeric value with citation -- PASS |
| "3,956 drug entries" | Open Targets knownDrugs | Numeric value with citation -- PASS |
| "dominant-negative dysfunction" (Section 5.1) | Mechanistic inference from interaction data | Appropriately qualified with evidence grade L2 -- PASS |
| "GJA1 trafficking disruption contributes to hypomyelination" (Section 5.3) | Inference from STRING interaction | Marked as L3 evidence grade -- PASS |
| "13 known transcripts" (Section 3) | Ensembl gene data | Verifiable with citation -- PASS |

**Potential concern:** The phrase "producing poisoned dimers that incorporate into growing microtubules and destabilize them from within" (Section 5.1) is a mechanistic narrative construction that synthesizes multiple data points. However, it is (a) consistent with the dominant-negative disease mechanism documented by OMIM and Open Targets, (b) appropriately graded L2, and (c) qualified with "are predicted to disrupt." This is faithful mechanistic synthesis, not hallucination.

**Minor gap:** Some interaction functional role descriptions in the STRING table (e.g., "Alpha-tubulin heterodimer partner," "Gap junction trafficking along microtubules") are brief functional annotations that could originate from STRING text-mining or from general biological knowledge. These are appropriately cited to the STRING interaction call but the exact wording may be paraphrased rather than verbatim from tool output.

---

## Synapse Grounding Score

**PENDING -- 0/10 (system maintenance, not scored)**

Synapse grounding verification was not performed. This score is excluded from the overall average pending infrastructure availability.

---

## Failure Classification

| Issue | Dimension | Failure Type | Severity | Recommendation |
|-------|-----------|-------------|----------|----------------|
| ASO compound lacks standard CURIE | Dim 1 | Justified absence | Minor | Track nL-TUBB4-001 for future ChEMBL/PubChem registration |
| STRING LOCATE step not explicitly cited | Dim 3 | Presentation failure | Minor | Add explicit `string_search_proteins("TUBB4A")` citation |
| OT pagination parameters not documented | Dim 5 | Documentation gap | Minor | Document `size`/`index` parameters in OT citations |
| Section-level grading instead of claim-level numeric | Dim 6 | Methodology gap | Minor | Add per-claim 0.00-1.00 scores alongside L1-L4 |
| PubMed full-text not analyzed | Dim 9 | Data gap | Moderate | Query top 5 TUBB4A+H-ABC publications via PubMed MCP |
| BioGRID interactions not retrieved | Dim 9 | Data gap | Minor | Query BioGRID ID 115655 for physical interaction evidence |
| No Graphiti persistence | Dim 9 | Protocol gap (Phase 6) | Moderate | Persist KG JSON to Neo4j/Graphiti backend |

---

## Overall Assessment

### Summary Scorecard

| Dimension | Score | Status |
|-----------|-------|--------|
| 1. CURIE Resolution | 9/10 | PASS |
| 2. Source Attribution | 9/10 | PASS |
| 3. LOCATE-RETRIEVE Pattern | 9/10 | PASS |
| 4. Disease CURIE | 10/10 | PASS |
| 5. OT Pagination | 8/10 | PASS |
| 6. Evidence Grading | 9/10 | PASS |
| 7. GoF Filter | N/A | N/A (dominant-negative, not GoF) |
| 8. Trial Validation | 9/10 | PASS |
| 9. Completeness | 8/10 | PASS |
| 10. Hallucination Risk | 9/10 | PASS (LOW) |
| **Synapse Grounding** | **PENDING** | **Excluded from average** |
| **Overall (9 scored dimensions)** | **80/90 = 8.9/10** | **PASS** |

### Verdict: **PASS**

**Average score: 8.9 / 10.0** (across 9 scored dimensions; Dim 7 GoF N/A excluded; Synapse Grounding pending)

### Strengths

1. **Exceptional entity resolution**: All 8 gene nodes carry 5+ cross-database identifiers validated across HGNC, Ensembl, UniProt, Entrez, and OMIM. The TUBB4A primary node has 11 distinct identifiers.
2. **ASO therapy discovery**: Identification of two N-of-1 ASO trials (NCT07222371, NCT06369974) is a significant non-obvious finding for a rare disease with no approved therapies.
3. **Mechanistic depth**: Section 5 provides 6 distinct mechanistic pathways linking TUBB4A interactions to H-ABC phenotypes, each with appropriate evidence grading.
4. **Contraindication analysis**: The report correctly identifies that 3,956 oncology tubulin drugs are contraindicated for H-ABC and explains why, preventing a dangerous misinterpretation.
5. **Complete disease CURIE resolution**: Both H-ABC and DYT4 resolved with MONDO, Orphanet, and OMIM identifiers.

### Recommendations for v2

1. Query PubMed via `@cyanheads/pubmed-mcp-server` for top 5 TUBB4A + H-ABC publications to ground mechanistic claims in primary literature.
2. Query BioGRID interactions for TUBB4A (ID: 115655) to complement STRING evidence.
3. Add per-claim numeric confidence scores (0.00-1.00) alongside L1-L4 grades.
4. Persist knowledge graph to Graphiti/Neo4j backend to complete Phase 6.
5. Document Open Targets pagination parameters explicitly in source citations.
6. Include STRING network visualization URL in report for visual reference.

---

## File Inventory

| File | Expected | Status |
|------|----------|--------|
| `tubb4a-v1-report.md` | Primary report | PRESENT |
| `tubb4a-v1-knowledge-graph.json` | Knowledge graph (27 nodes, 27 edges) | PRESENT |
| `tubb4a-v1-knowledge-graph-json.txt` | KG text copy | PRESENT |
| `tubb4a-v1-quality-review.md` | This quality review | PRESENT |
| `tubb4a-v1-knowledge-graph - Copy.json:Zone.Identifier` | Windows zone identifier artifact | PRESENT (non-essential) |

---

*Quality review performed against the 10-dimension Fuzzy-to-Fact quality assessment framework (lifesciences-reporting-quality-review skill v2026-02).*
